Investment Thesis
BioVie is a pre-revenue pharmaceutical company with significant operational losses (-$11.5M operating income) and negative free cash flow (-$7.5M), indicating it is in active development phase with no commercial revenue generation. While the company maintains adequate liquidity with $20.5M cash against only $3.2M liabilities, current burn rate suggests runway of approximately 2.7 years at existing consumption levels. The absence of revenue combined with mounting losses and persistent negative returns on assets (-27.0%) and equity (-31.5%) indicates the company is capital-intensive with unproven commercial viability.
Strengths
- Strong liquidity position with $20.5M cash and 7.25x current ratio providing near-term operational runway
- Minimal debt burden with only $62.5K long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk
- Increased insider activity with 8 Form 4 filings in last 90 days suggesting management confidence or option exercises
Risks
- Zero revenue with no commercial products generating sales, typical pre-clinical or early-stage biotech phase risk
- Negative operating cash flow of -$7.5M annually with current cash providing limited runway before requiring capital raise or achieving major milestones
- Persistent unprofitability with $11.5M operating losses and -31.5% ROE indicating inability to generate returns from equity capital invested
- Negative interest coverage of -1451.3x reflects operating losses exceeding any interest obligations and operational distress
Key Metrics to Watch
- Revenue generation from any approved product candidates or milestone achievement
- Monthly cash burn rate trend to assess sustainability of current runway
- Clinical trial progression and regulatory approvals for lead drug candidates
- Operating expense management and gross margin upon revenue initiation
- Capital raise requirements and dilution impact on existing shareholders
Financial Metrics
Revenue
0.0
Net Income
-6.1M
EPS (Diluted)
$-1.70
Free Cash Flow
-7.5M
Total Assets
22.5M
Cash
20.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-31.5%
ROA
-27.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.25x
Quick Ratio
7.25x
Debt/Equity
0.00x
Debt/Assets
14.4%
Interest Coverage
-1,451.34x
Long-term Debt
62.5K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T03:08:16.978478 |
Data as of: 2025-12-31 |
Powered by Claude AI